Search results for "malattie"

showing 10 items of 1963 documents

Altered CD94/NKG2A and perforin expression reduce the cytotoxic activity in malignant pleural effusions.

2010

CD94/NKG2A is an inhibitory receptor expressed by NK cells and cytotoxic lymphocytes and, upon activation by HLA-E, downregulates the cytolytic activities of these cells thus representing a tumour immune escape mechanism. This study was aimed at assessing whether cytotoxic lymphocytes (CD8+) and NK cells from malignant pleural effusions have a deregulated expression of CD94/NKG2A. The expression of membrane CD94/NKG2A and perforin was evaluated by flow-cytometry in CD8+ and NK cells from pleural effusions and autologous peripheral blood of cancer (n=19) and congestive heart failure (CHF) (n=11) patients. Intracellular CD94/NKG2A expression was evaluated by flow-cytometry in pleural effusion…

Cancer ResearchPleural effusionLymphocyteSettore MED/10 - Malattie Dell'Apparato RespiratorioCD8-Positive T-LymphocytesInterleukin 21Pleural diseaseNeoplasmsmedicineMalignant pleural effusionCytotoxic T cellHumansAgedHeart Failurebiologybusiness.industryPerforinCancerCD8-Positive T-LymphocyteMiddle Agedmedicine.diseaseNatural Killer T-CellPleural Effusion Malignantmedicine.anatomical_structureOncologyPerforinCase-Control StudiesImmunologybiology.proteinNeoplasmNatural Killer T-CellsTumor EscapebusinessCase-Control StudieNK Cell Lectin-Like Receptor Subfamily DHumanT-Lymphocytes CytotoxicEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells

2008

Resistance to imatinib mesylate is an emergent problem in the treatment of Bcr-Abl expressing myelogenous leukemias and additional therapeutic strategies are required. We observed that galangin, a non-toxic, naturally occurring flavonoid was effective as anti-proliferative, and apoptotic agent in Bcr-Abl expressing K562 and KCL22 cells and in imatinib mesylate resistant K562-R and KCL22-R cells. Galangin induced an arrest of cells in G0–G1phase of cell cycle and a decrease in pRb, cdk4, cdk1, cycline B levels; moreover, it was able to induce a monocytic differentiation of leukemic Bcr-Abl+ cells. Of note, galangin caused a decrease in Bcl-2 levels and markedly increased the apoptotic activi…

Cancer ResearchSettore MED/17 - Malattie InfettiveSettore MED/06 - Oncologia MedicaApoptosisPharmacologyResting Phase Cell CyclePiperazineschemistry.chemical_compoundCell Line TumorLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCytotoxic T cellChrysinneoplasmsFlavonoidsLeukemiaG1 PhaseApoptosiCell DifferentiationImatinibmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGalanginLeukemiaPyrimidinesImatinib mesylateOncologychemistryDrug Resistance NeoplasmImatinibBenzamidesSettore BIO/14 - FarmacologiaImatinib MesylateK562 CellsFisetinBcr-AblK562 cellsmedicine.drugCancer Letters
researchProduct

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective cli…

2022

: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyse…

Cancer Researchlenalidomidedexamethasone; elotuzumab; lenalidomide; multiple myeloma; salvage therapydexamethasoneHematologyGeneral MedicineAntibodies Monoclonal HumanizedelotuzumabThalidomidemultiple myelomaOncologyAntineoplastic Combined Chemotherapy ProtocolsHumanssalvage therapySettore MED/15 - Malattie del SangueFollow-Up StudiesRetrospective StudiesHematological Oncology
researchProduct

Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study

2014

Purpose We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients and Methods Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after disconinuation of LMWH, and the secondar…

Cancer Researchmedicine.medical_specialtymedicine.drug_classDeep veinPopulationLow molecular weight heparinSettore MED/42 - Igiene Generale E ApplicataGroup BSettore MED/15 - Malattie Del SangueInternal medicineresidual vein thrombosis low molecular weight heparin cancer patientsmedicineeducationFirst episodeeducation.field_of_studybusiness.industrylow molecular weight heparinHazard ratioantivitamin K; low molecular weight heparin; nadroparinCancermedicine.diseaseThrombosisSurgerymedicine.anatomical_structureOncologynadroparinantivitamin Kbusiness
researchProduct

Candida spp. infections after abdominal urgent surgery: comparative analysis of histologic data for which microbiological results were positive for C…

2015

EV0515 ePoster Viewing Diagnostic/laboratory methods other than molecular Candida spp. infections after abdominal urgent surgery: comparative analysis of histologic data for which microbiological results were positive for Candida spp. V. Rodolico1, G. Gulotta1, L. Montana1, G. Salamone1, D.C. Paola1 1Department of Sciences for Health Promotion and Mother Child Care, Palermo, Italy Objectives: Microbiological identification is justified when the yeast is isolated from a sterile site, the potential clinical impact of identified isolates from non sterile sites such as intra- abdominal organs don’t help the clinicians to determine whether the strain isolate represents contamination, colonizatio…

Candida infection surgery hystopathological diagnosisSettore MED/18 - Chirurgia GeneraleSettore MED/17 - Malattie InfettiveSettore MED/08 - Anatomia Patologica
researchProduct

Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

2021

n/a

Caratmedicine.medical_specialtybusiness.industryMEDLINESettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.diseaseRhinitis AllergicAsthmaTest (assessment)Internal medicineHumansImmunology and AllergyMedicinebusinessRhinitisAsthmaThe Journal of Allergy and Clinical Immunology: In Practice
researchProduct

Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive r…

2011

Background— Diastolic dysfunction associated with high blood pressure (BP) leads to cardiac remodeling and fibrosis and progression to congestive heart failure. B-type natriuretic peptide (BNP) has BP-lowering, antifibrotic, and antihypertrophic properties, which makes BNP an attractive agent for attenuating the adverse cardiac remodeling associated with hypertension. In the current study, we tested the effects of sustained cardiac proBNP gene delivery on BP, cardiac function, and remodeling in spontaneously hypertensive rats (SHR). Methods and Results— We used the myocardium-tropic adeno-associated virus serotype 9 (AAV9) vector to achieve continuously enhanced cardiac rat proBNP expressi…

Cardiac function curvemedicine.medical_specialtymedicine.drug_classBNP; Natyriuretic peptides; hypertensive heart diseaseDiastolePhysiology (medical)Internal medicinemedicineNatriuretic peptideNatyriuretic peptidescardiovascular diseasesVentricular remodelingEjection fractionbusiness.industryheart failure natriuretic peptide hypertension.medicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareHypertensive heart diseaseBlood pressureEndocrinologyHeart failurecardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesshypertensive heart diseasehormones hormone substitutes and hormone antagonistsBNP
researchProduct

Pulmonary haemodynamics in obstructive sleep apnoea.

1995

In patients with obstructive sleep apnoea syndrome (OSAS), pulmonary haemodynamics can show both transient perturbations during sleep and permanent alterations. During sleep, repeated fluctuations in pulmonary artery pressure and pulmonary wedge pressure, coincident with apnoeas, can be observed. Calculation of transmural pressure values is preferable to intravascular pressures in OSAS, due to the marked swings in intrathoracic pressure associated with obstructive apnoeas. Pulmonary artery pressure may progressively increase during sleep, particularly in close sequences of highly desaturating apnoeas. Apnoea-induced hypoxia appears as the most important determinant of this pulmonary artery …

Cardiac outputPulmonary and Respiratory MedicineCardiac outputmedicine.medical_specialtyHypertension PulmonaryVentricular Dysfunction RightCognitive NeuroscienceSleep REMSettore MED/10 - Malattie Dell'Apparato RespiratorioBehavioral Neurosciencestomatognathic systemPhysiology (medical)Internal medicinemedicine.arteryHumansMedicineRespiratory functionWakefulnessHypoxiaPulmonary wedge pressureLungSleep Apnea Obstructivebusiness.industryHemodynamicsSleep apneaGeneral MedicineStroke volumeHypoxia (medical)medicine.diseasePulmonary artery pressurePulmonary hypertensionnervous system diseasesrespiratory tract diseasesObstructive sleep apneaOphthalmologyStroke volumemedicine.anatomical_structureNeurologyObstructive sleep apnoeaVentricleAnesthesiaPulmonary arteryDentistry (all)CardiologyRight ventricleNeurology (clinical)medicine.symptombusinessJournal of sleep research
researchProduct

La caratterizzazione della Cardiomiopatia dilatativa mediante tecniche diagnostiche di primo e secondo livello.

2012

Cardiomiopatia dilatativaSettore MED/15 - Malattie Del Sangue
researchProduct

Rare cardiomyopathies: Diagnostic features

2013

Cardiomyopathies (CM) are an important and heterogeneous group of diseases affecting the myocardium. They can induce mechanical and/or electrical disorders and are due to a variety of causes, they frequently are genetic. However, since their high number and their clinical complexity, the identification is still a challenge. Echocardiography is a very useful tool in the assessment of CM. In this review we aim to define the typical clinical features and to discuss the main diagnostic tool, above all echocardiography that can help physicians in the correct assessment of CM.

Cardiomyopathy RestrictiveCardiomyopathyRestrictiveReproducibility of ResultsSettore MED/11 - Malattie Dell'Apparato CardiovascolareSensitivity and Specificitycardiomyopahies echocardiographyDiagnosis DifferentialArrhythmogenic Right Ventricular Dysplasia; Cardiomyopathies; Cardiomyopathy Restrictive; Diagnosis Differential; Fabry Disease; Friedreich Ataxia; Humans; Predictive Value of Tests; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Takotsubo Cardiomyopathy; EchocardiographyFriedreich AtaxiaPredictive Value of TestsRisk FactorsTakotsubo CardiomyopathyEchocardiographyDiagnosisDifferentialFabry DiseaseHumansCardiomyopathiesArrhythmogenic right ventricular dysplasia; Cardiomyopathy restrictive; Fabry diseaseArrhythmogenic Right Ventricular Dysplasia
researchProduct